RxDoctor Payments Data

Victorio Pidlaoan, MD

Gastroenterology · Modesto, CANPI 1871813097

Payments from drug & device makers

$2,675in general payments, 2019–2025

Across 139 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Boston Scientific$650
  • Johnson & Johnson$273
  • Takeda Pharmaceuticals U.S.A., Inc.$100
  • Lilly USA, LLC$100
  • Braintree Laboratories, Inc.$27
  • plus $59 from 3 others

What the payments were for

  • Travel & lodging$27010%
  • Food & beverage$2,37089%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,675 in reported general payments places this provider in the 50th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$190,726
Medicare patients
615
Services billed
1,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab14$87,222
OzempicSemaglutide60$86,961
LinzessLinaclotide22$26,246
Mesalamine ErMesalamine16$3,720
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates35$2,027
Pantoprazole Sodium154$1,984
Omeprazole75$1,733
Ursodiol15$978
CholestyramineCholestyramine (With Sugar)12$909
Sucralfate28$565
Bupropion XlBupropion Hcl12$523
Lactulose13$444
Ondansetron OdtOndansetron12$297
Metformin Hcl ErMetformin Hcl11$224
Mirtazapine16$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,466$26,24622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →